title: Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study.
abstract: BACKGROUND
  Lymphovascular invasion (LVI) identified following pathologic slide review has been shown to be an independent predictor of recurrence-free survival (RFS) and cancer-specific survival (CSS) in a multicenter series of patients undergoing radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). However, the validity of LVI in everyday practice, where pathologic re-review of all slides is uncommon, has not been assessed.
  
  
  OBJECTIVE
  Our aim was to evaluate the prognostic role of LVI in an international cohort of patients treated with RNU for UTUC without pathologic slide review.
  
  
  METHODS
  Data from 762 patients treated with RNU for UTUC without neoadjuvant chemotherapy were collected at nine centers located in Europe, Asia, and Canada.
  
  
  METHODS
  We evaluated patients' characteristics, RFS, and CSS.
  
  
  CONCLUSIONS
  LVI was present in 148 patients (19.4%). At a median follow-up of 34 mo, 23.5% of the patients developed disease recurrence and 19.8% died of UTUC. The 5-yr RFS and CSS rates were 79.3% and 82.1%, respectively, in the absence of LVI compared with 45.1% and 45.8%, respectively, in the presence of LVI (p values <0.0001). On multivariable Cox regression analyses, LVI was an independent predictor of RFS (hazard ratio [HR]: 3.3; p=0.005) and CSS (HR: 5.9; p<0.0001). Similarly, among patients with pN0/Nx disease, LVI was an independent predictor of RFS (HR: 2.1; p=0.001) and CSS (HR: 2.3; p<0.0001).
  
  
  CONCLUSIONS
  In a large multicenter series of patients treated with RNU for UTUC and for which no pathologic slide review was performed, LVI was present in approximately 20% and was an independent predictor of both RFS and CSS. LVI status should always be included in the pathologic report of RNU specimens, and patients with LVI should be considered for adjuvant therapy studies.
authors.affiliation: University of Padua, Padua, Italy.
authors.forename: Giacomo
authors.initials: G
authors.lastname: Novara
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Wassim
authors.initials: W
authors.lastname: Kassouf
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Walton
authors.forename: Hans-Martin
authors.initials: HM
authors.lastname: Fritsche
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Bastian
authors.forename: Juan I
authors.initials: JI
authors.lastname: Martínez-Salamanca
authors.forename: Christian
authors.initials: C
authors.lastname: Seitz
authors.forename: R John
authors.initials: RJ
authors.lastname: Lemberger
authors.forename: Maximilian
authors.initials: M
authors.lastname: Burger
authors.forename: Assaad
authors.initials: A
authors.lastname: El-Hakim
authors.forename: Shiro
authors.initials: S
authors.lastname: Baba
authors.forename: Guido
authors.initials: G
authors.lastname: Martignoni
authors.forename: Amit
authors.initials: A
authors.lastname: Gupta
authors.forename: Pierre I
authors.initials: PI
authors.lastname: Karakiewicz
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Ficarra
authors.forename: Shahrokh F
authors.initials: SF
authors.lastname: Shariat
mesh_terms: D000368:Aged; D001808:Blood Vessels / Q000473:pathology*; D002277:Carcinoma / Q000473:pathology*; D018572:Disease-Free Survival; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008198:Lymph Nodes / Q000473:pathology; D008208:Lymphatic System / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009361:Neoplasm Invasiveness / Q000473:pathology*; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D014571:Urologic Neoplasms / Q000401:mortality / Q000473:pathology*; D019459:Urothelium / Q000473:pathology*